1-甲基-4-(3-硝基苯基)哌嗪 | 148546-97-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-甲基-4-(3-硝基苯基)哌嗪
• 中文别名: 1-甲基-4-(3-硝基苯基)哌嗪二盐酸盐；1-甲基-4-(3'-硝基苯基)哌嗪
• 英文名称: 1-methyl-4-(3-nitrophenyl)piperazine
• CAS: 148546-97-8
• 化学式: C₁₁H₁₅N₃O₂
• mdl: MFCD08435858
• 分子量: 221.259
• InChiKey: IIRKKCDXJIXWHI-UHFFFAOYSA-N

物化性质

• 熔点：
  59.5-62.5
• 沸点：
  351.9±37.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933599090
• 储存条件：
  室温、密封、干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Methyl-4-(3-nitrophenyl)piperazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methyl-4-(3-nitrophenyl)piperazine
CAS number: 148546-97-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H15N3O2
Molecular weight: 221.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-4-(3-硝基苯基)哌嗪 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 3-(4-甲基哌嗪-1-基)苯胺
  参考文献：
  名称：

  2,4-二氨基嘧啶衍生物作为有效造血祖细胞激酶 1 (HPK1) 抑制剂的设计、合成和生物学评价

  摘要：

  HPK1也称为MAP4K1，属于哺乳动物STE20样蛋白丝氨酸/苏氨酸激酶类别。其生理功能涉及T细胞信号的下调，被视为肿瘤免疫学新的免疫检查点。在这项研究中，我们开始对热门化合物进行研究，重点关注结构优化和 SAR 探索，以确定一类新型 2,4-二氨基嘧啶 HPK1 抑制剂。值得注意的是，该化合物对 HPK1 激酶表现出显着的抑制作用 (IC = 0.15 nM)，显着抑制下游接头蛋白 SLP76 的磷酸化 (pSLP76 IC = 27.92 nM)，并有效刺激 T 细胞激活标记物 IL-2 的分泌（EC = 46.64 nM）。微粒体稳定性测定，化合物在 T = 38.2 分钟和 CL = 36.4 µL·min·mg 蛋白质的 HLM 中表现出中等稳定性。在药代动力学研究中，与参考化合物相比，化合物的血浆暴露量增加（AUC = 644 ng·h·mL），半衰期延长（T = 9.98 h），血浆清除率降低（CL

  DOI：

  10.1016/j.bioorg.2024.107454
• 作为产物：
  描述：

  N-甲基哌嗪 、 1-碘-3-硝基苯 在 copper(l) iodide 、 caesium carbonate 、 L-脯氨酸 作用下， 以 二甲基亚砜 为溶剂， 反应 16.0h， 以34.9%的产率得到1-甲基-4-(3-硝基苯基)哌嗪
  参考文献：
  名称：

  [EN] NOTCH INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE NOTCH ET LEURS UTILISATIONS

  摘要：

  本公开的内容包括用于抑制Notch的化合物及其用途。

  公开号：

  WO2021237112A1

文献信息

• [EN] DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS<br/>[FR] DIARYLURÉES EN TANT QUE MODULATEURS ALLOSTÉRIQUES DE CB1
  申请人：RTI INT

  公开号：WO2018209030A1

  公开（公告）日：2018-11-15

  The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.

  本发明提供了新颖的二芳基脲衍生物（式（I）化合物）及其用途。本发明的化合物被证明是CB1受体的变构调节剂，因此对于治疗由CB1介导的疾病和症状是有用的。
• Synthesis of 2-Arylbenzothiazol-5-amines from N,N-Dialkyl-3-nitroanilines
  作者：Tung T. Nguyen、Nam T. S. Phan、Hang T. Pham、Tuan H. Ho、Duy Q. Do、Kim L. H. Nguyen

  DOI：10.1055/s-0040-1706470

  日期：2020.11

  We report a simple method for coupling of N,N-dialkyl-3-nitroarenes, elemental sulfur, and activated sp3 C–H bonds in 2-methylazaarenes or arylacetic acids to afford derivatives of 2-arylbenzothiazol-5-amines. Only DABCO base was required, and many heterocycles such as imidazoles, oxazoles, quinolines, and thiophenes were compatible with the reaction conditions. Our approach offers a simple route to useful substituted thiazol-5-amines from commercially available nitroarenes.

  我们报道了一种简单的方法，用于耦合N，N-二烷基-3-硝基芳烃，元素硫和2-甲基氮杂芳烃或芳乙酸中的活化sp3 C-H键，以提供2-芳基苯并噻唑-5-胺衍生物。仅需要DABCO碱，并且许多杂环如咪唑，噁唑，喹啉和噻吩都与反应条件兼容。我们的方法提供了一种从商业上可用的硝基芳烃合成有用的取代噻唑-5-胺的简单途径。

• Functionalization of Primary C–H Bonds in Picolines toward Pyridylthioamides
  作者：Tuan H Ho、Ha H K Le、Tuong A To、Tung T Nguyen、Nam T S Phan

  DOI：10.1246/bcsj.20200004

  日期：2020.6.15

  We report a method for coupling of nitroarenes, 2- or 4-methylazaarenes, and elemental sulfur to afford (2-pyridyl)aryl thioamides. Good tolerance of functionalities was observed, including primary...

  我们报告了一种偶联硝基芳烃、2-或 4-甲基氮杂芳烃和元素硫以提供 (2-吡啶基) 芳基硫代酰胺的方法。观察到良好的功能耐受性，包括主要...
• [EN] N-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES N-SUBSTITUÉS À TITRE D'INHIBITEURS DE KINASES
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014125410A1

  公开（公告）日：2014-08-21

  The present invention provides N-substituted novel heterocyclic derivatives of formula (I) as protein kinase inhibitors, in which R1, R2 and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了式（I）的N-取代新异环衍生物作为蛋白激酶抑制剂，其中R1、R2和'n'的含义与规范中给出的含义相同，并且其药学上可接受的盐在治疗和预防疾病或紊乱方面具有用处，特别是它们在抑制激酶酶有优势的疾病或紊乱中的用途，更特别是BTK酶。本发明还提供了合成和给予激酶抑制剂化合物的方法。本发明还提供了包含至少一种激酶抑制剂化合物的药物配方，以及药学上可接受的载体、稀释剂或赋形剂。
• Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
  申请人：——

  公开号：US20030055055A1

  公开（公告）日：2003-03-20

  The present invention relates to novel benzimidazole derivatives, pharmaceutical composition containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA receptor complex, and in particular for inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children. The compounds of the invention may also be used by veterinarians.

  本发明涉及新型苯并咪唑衍生物，含有这些化合物的药物组合物，以及使用这些化合物进行治疗的方法。本发明的化合物在治疗对GABA受体复合物调节敏感的中枢神经系统疾病和紊乱方面具有用途，特别是用于诱导和维持麻醉、镇静和肌肉松弛，以及用于对抗儿童的热性惊厥。本发明的化合物也可以被兽医使用。